Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial Spotlight
Multiple solid tumors
Phase 1 CLSP-5282 KRAS G12V–HLA-A03:01 T-cell engager in solid tumors
This Phase 1 open-label, multicenter, dose-escalation and expansion trial (SENTINEL-101) evaluates CLSP-5282 in adults whose advanced/metastatic solid tumors harbor KRAS G12V and who are HLA-A03:01 positive.…
NCT07650357 First-in-human - New trial
Multiple solid tumors
Phase 1 Lattice Radiotherapy (spatially fractionated IMRT) adds vertex “boosts” for bulky tumors
This Duke University pilot interventional study tests whether adding Lattice Radiation Therapy (LRT)—a spatially fractionated form of intensity-modulated radiation therapy (IMRT)—to standard palliative external-beam…
NCT07647679 Exploratory - New trial
Multiple solid tumors
Phase 1 ACM-CpG TLR9 agonist polymer-lipid nanoparticle for peritoneal metastases
This Phase 1, open-label, dose-escalation study (standard 3+3) tests escalating intraperitoneal injections of ACM-CpG to define safety, dose-limiting toxicities, and the maximum tolerated dose/optimal biologic dose…
NCT07658196 Exploratory - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result Spotlight
Melanoma
Ipilimumab (CTLA-4) + nivolumab–relatlimab (PD-1/LAG-3) drives 69% MPR (63% pCR) in resectable stage III melanoma—at the cost of 26% G3 and 1 G5 myocarditis
Neoadjuvant INR combines low-dose ipilimumab (CTLA-4 blockade) with fixed-dose nivolumab–relatlimab (PD-1/LAG-3 blockade) to deepen pathologic responses while keeping treatment short. In this Phase II trial in…
NCT06295159 - Trial result Spotlight
Melanoma
Nivolumab + Relatlimab (PD-1/LAG-3) Adds 10% Absolute 5-Year OS in 1L Melanoma
Nivolumab is a PD-1 inhibitor and relatlimab is a LAG-3 inhibitor evaluated as a fixed-dose combination versus nivolumab alone in the randomized, double-blind Phase 3 RELATIVITY-047 first-line trial in…
NCT03470922 - Trial result
Melanoma
TIL adoptive cell therapy (autologous) delivers 22% ORR in metastatic uveal melanoma—responses track with UMIS-selected, tumor-reactive products
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy—generated from resected metastases, expanded ex vivo, then given after cyclophosphamide/fludarabine lymphodepletion with high-dose IL-2—was tested…
NCT03467516 - Trial result
Melanoma
Adaptive encorafenib/binimetinib (BRAF/MEK) + nivolumab cuts Grade 3+ AEs while preserving long-run disease control in BRAF V600E melanoma
Encorafenib (BRAF inhibitor) + binimetinib (MEK inhibitor) were given either continuously or via patient-specific adaptive scheduling (ctDNA- and imaging-calibrated mathematical model), with nivolumab (anti–PD-1)…
NCT03543969 - Trial result
Melanoma
Recent anti-CTLA-4 (ipilimumab) linked to IL-6–high immunosuppressive profile and ~6× shorter OS on PD-L1 + CD40/4-1BB adenoviral gene therapy in PD-1–refractory melanoma
LOKON003 combines an anti–PD-L1 antibody with a replication-competent adenoviral immunogene therapy designed to stimulate CD40 and 4-1BB signaling (NCT04123470) in anti–PD-1–refractory metastatic melanoma (Phase…
NCT04123470 - Trial result
Melanoma
Brenetafusp (PRAME×CD3 ImmTAC) shows 17% ORR at 160µg in late-line melanoma, with mostly low-grade CRS and no irAE recurrence
Brenetafusp (IMC-F106C) is a PRAME-targeted ImmTAC bispecific (PRAME×CD3) designed to redirect polyclonal T cells into PRAME-expressing tumors; in this Phase 1 study (NCT04262466), HLA-A*02:01+ advanced melanoma…
NCT04262466 - Trial result
Melanoma
Botensilimab (Fc‑enhanced anti‑CTLA‑4) + balstilimab (anti‑PD‑1) delivers 22% ORR in dual ICI‑refractory cutaneous melanoma
Botensilimab (BOT) is an Fc‑engineered anti‑CTLA‑4 antibody designed to enhance T‑cell priming and Treg depletion, and balstilimab (BAL) is an anti‑PD‑1; both were evaluated in the open-label global Phase 2 C‑800‑23…
NCT05529316 - Trial result
Melanoma
Imneskibart (AU-007) IL-2–CD25 “decoy” antibody + low-dose aldesleukin drives tumor shrinkage in CPI-refractory melanoma (early PFS signal)
Imneskibart (AU-007) is an AI-designed anti–IL-2 monoclonal antibody that blocks IL-2 binding to CD25 (trimeric IL-2R) while preserving signaling through CD122/CD132 (dimeric IL-2R), aiming to expand Teff/NK without…
NCT05267626 - Trial result
Melanoma
IO102-IO103 (PD-L1/IDO peptide vaccine) + nivolumab–relatlimab (PD-1/LAG-3) posts 60% ORR in 1L unresectable melanoma
IO102-IO103 is a subcutaneous peptide vaccine targeting PD-L1 and IDO-expressing tumor and immunosuppressive cells, combined here with nivolumab–relatlimab (dual PD-1/LAG-3 checkpoint blockade) in a multicenter Phase…
NCT05912244 - Trial result
Melanoma
OBX-115 (ACZ-inducible mbIL15–armored TIL) drives 67% ORR in post-ICI advanced melanoma without high-dose IL2
OBX-115 is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express membrane-bound IL15 (mbIL15) under small-molecule control with acetazolamide (ACZ), designed to avoid the traditional…
NCT06060613 - Trial result
Melanoma
Atezolizumab + Tiragolumab (PD-L1/TIGIT) Shows Index Node pCR Can Miss Melanoma
Atezolizumab is an anti–PD-L1 antibody and tiragolumab is an anti-TIGIT antibody evaluated in a preplanned NeoACTIVATE Arm C substudy (NCT03554083) asking whether clipped index lymph node (ILN) pathology can…
NCT03554083 - Trial result Spotlight
Colorectal cancer
Ivonescimab (PD-1×VEGF bispecific) + mFOLFOX6 posts 70.8% ORR and 100% DCR in 1L unresectable mCRC (Phase 2)
Ivonescimab is an investigational tetrameric bispecific antibody co-targeting PD-1 and VEGF, here combined with oxaliplatin/5-FU/leucovorin (mFOLFOX6) as first-line therapy in a multiregional Phase 2 trial…
NCT05382442 - Trial result Spotlight
Colorectal cancer
Nivolumab + ipilimumab (PD-1 + CTLA-4) improves long-term treatment-free survival vs nivolumab in MSI-H/dMMR mCRC
Nivolumab + ipilimumab (NIVO + IPI), a dual immune checkpoint regimen targeting PD-1 and CTLA-4, was compared with nivolumab (PD-1) monotherapy in the Phase 3 CheckMate 8HW trial in metastatic colorectal cancer with…
NCT04008030 - Trial result Spotlight
Colorectal cancer
Tislelizumab (PD-1) neoadjuvant drives 78.6% pCR + ctDNA MRD clears fast in dMMR/MSI-H colon cancer
Tislelizumab is an anti–PD-1 monoclonal antibody engineered to minimize Fcγ receptor binding; here it was given as neoadjuvant monotherapy (200mg IV Q3W ×4, then up to 8+ cycles per MDT) with tumor-informed ctDNA MRD…
NCT06262581 - Trial result Spotlight
Colorectal cancer
Onvansertib (PLK1 inhibitor) + FOLFIRI/Bev lifts ORR to 72% and improves PFS signal in 1L RAS-mut mCRC
Onvansertib (Onv) is an oral, selective polo-like kinase 1 (PLK1) inhibitor combined here with standard doublet chemotherapy plus bevacizumab (FOLFIRI+Bev or FOLFOX+Bev) in the randomized Phase 2 CRDF-004 trial…
NCT06106308 - Trial result
Colorectal cancer
ABFOLFOX (PD-L1 + VEGF + FOLFOX) drives immune-activated CRLM states, with 35% durable control
Atezolizumab (anti–PD-L1) + bevacizumab (anti-VEGF) + leucovorin/5-FU/oxaliplatin (FOLFOX) was evaluated as neoadjuvant therapy for unresectable colorectal liver metastases (CRLM) in a prospectively registered cohort…
NCT03698461 - Trial result
Colorectal cancer
Ozekibart (INBRX-109) DR5 agonist + FOLFIRI delivers 23% ORR in 4L+ metastatic CRC
Ozekibart (INBRX-109) is a next-generation tetravalent death receptor 5 (DR5) agonist designed to induce tumor cell apoptosis; here it was combined with FOLFIRI in an open-label Phase 1 expansion cohort (C4d;…
NCT03715933 - Trial result
Colorectal cancer
Ad5.F35-GUCY2C-PADRE (GUCY2C-directed adenoviral vaccine) drives dose-dependent T-cell immunity and signals improved 2-year RFS in resected CRC
Ad5.F35-GUCY2C-PADRE is an off-the-shelf chimeric Ad5/35 vector vaccine targeting the intestinal tumor antigen GUCY2C and incorporating PADRE to enhance CD4+ help, designed to bypass pre-existing anti-Ad5…
NCT04111172 - Trial result
Colorectal cancer
Zongertinib (selective irreversible HER2 TKI) drives 45% ORR with mostly grade 1 diarrhea in HER2+ CRC
Zongertinib is an irreversible, HER2-selective tyrosine kinase inhibitor designed to spare wild-type EGFR (aiming to reduce classic EGFR-TKI rash/diarrhea) and was evaluated as monotherapy in a pooled subgroup of…
NCT04886804 - Trial result
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) links early ctDNA clearance to longer survival in chemorefractory mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor, and panitumumab is an anti-EGFR monoclonal antibody; in the Phase 3 CodeBreaK 300 trial (NCT05198934) in chemorefractory KRAS G12C–mutant mCRC, this analysis tested…
NCT05198934 - Trial result
Colorectal cancer
ST316 β-Catenin/BCL9 Antagonist Reaches 46.7% ORR With 2L FOLFIRI/Bev in MSS mCRC
ST316 is a first-in-class IV peptide antagonist of the β-catenin–BCL9/9L interaction, designed to suppress oncogenic Wnt/β-catenin transcription while sparing physiologic Wnt signaling. In the ongoing Phase 1/2…
NCT05848739 - Trial result
Colorectal cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) c-Met–targeted topo-1 ADC posts 37% ORR in platinum-resistant ovarian cancer
Telisotuzumab adizutecan (Temab-A; ABBV-400) is a c-Met protein–targeting antibody–drug conjugate delivering a topoisomerase 1 inhibitor payload; in this Phase 1 open-label basket cohort (NCT06084481), patients with…
NCT06084481 - Trial result
Colorectal cancer
Leronlimab (CCR5 mAb) + TAS-102/Bev shows early ctDNA drops and 100% stable disease in refractory mCRC (CLOVER)
Leronlimab (LRM) is a subcutaneous anti-CCR5 humanized monoclonal antibody being added to the current late-line standard regimen trifluridine/tipiracil (TAS-102) plus bevacizumab in the open-label Phase 2 CLOVER…
NCT06699836 - Trial result
Colorectal cancer
ctDNA (MRD)-guided ACT (capecitabine±oxaliplatin) cuts 3-year recurrence in stage II MSS colon cancer
CIRCULATE (AIO KRK-0217/ABCSG; NCT04089631) used a tumor-informed NGS ctDNA assay post-op in stage II pMMR/MSS colon cancer: ctDNA+ patients were randomized to adjuvant chemotherapy (6 mo capecitabine or 3–6 mo…
NCT04089631 - Trial result
Colorectal cancer
EC (encorafenib+BRAF inhibitor) + cetuximab (EGFR mAb) + FOLFIRI cuts PFS risk ~56% in 1L BRAF V600E mCRC
Encorafenib (BRAF inhibitor) plus cetuximab (EGFR antibody) was combined with FOLFIRI chemotherapy as first-line treatment in BREAKWATER Cohort 3 (Phase 3, open-label; NCT04607421) for untreated BRAF V600E–mutant…
NCT04607421 - Trial result
Colorectal cancer
Lycopene (tomato-carotenoid) intake linked to ~40% lower recurrence/death risk in stage III colon cancer
In a prospective cohort nested within the Phase III CALGB (Alliance)/SWOG 80702 adjuvant trial (NCT01150045), post-diagnosis lycopene (a non–provitamin A carotenoid largely derived from tomato-based foods; diet ±…
NCT01150045
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.